Home

Insights

Dividend

Suven Life Sciences Ltd dividend

Suven Life Sciences Ltd dividend

download
stocks purchased

₹ 0.6 Cr

Volume transacted

stocks purchased

42.2 K

stocks traded

Last Updated time: 14 Jul 15:30 PM

Image

Suven Life Sciences Ltd

NSE: SUVEN

DPS

--

Last updated : FY 2024

Key Highlights

    The Dividend per Share of Suven Life Sciences Ltd is ₹ 0 as of 2024 .a1#The Dividend Payout of Suven Life Sciences Ltd changed from 48.72 % on March 2019 to 0 % on March 2024 . This represents a CAGR of -100.00% over 6 years. a1#The Latest Trading Price of Suven Life Sciences Ltd is ₹ 132.6 as of 12 Jul 15:30 .a1#The Market Cap of Suven Life Sciences Ltd changed from ₹ 3320 crore on March 2019 to ₹ 2174 crore on March 2024 . This represents a CAGR of -6.82% over 6 years. a1#The Revenue of Suven Life Sciences Ltd changed from ₹ 9.98 crore to ₹ 6.67 crore over 8 quarters. This represents a CAGR of -18.25% a1#The EBITDA of Suven Life Sciences Ltd changed from ₹ -14.64 crore to ₹ -26 crore over 8 quarters. This represents a CAGR of 33.27% a1#The Net Pr of Suven Life Sciences Ltd changed from ₹ -16.33 crore to ₹ -26.54 crore over 8 quarters. This represents a CAGR of 27.48% a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

Share Price Vs Dividend Yield

swot
swot

Company Fundamentals For Suven Life Sciences Ltd

Market Cap

2,891 Cr

EPS

0.0

P/E Ratio (TTM) *

0.0

P/B Ratio (TTM) *

10.7

DTE *

0.0

ROE *

-38.9

ROCE *

-39.1

Dividend Yield *

0

DPS *

0

Dividend Payout *

0

Ann.Dividend % *

0

* All values are consolidated

Last Updated time: 14 Jul 15:30 PM

* All values are consolidated

Last Updated time: 14 Jul 15:30 PM

×

Historical Dividend Payout of Suven Life Sciences Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Suven Life Sciences Ltd

Period
Mar '1949
Mar '200
Mar '210
Mar '220
Mar '230
Mar '240

* All values are a in %

Dividend per Share (DPS) Over Time

×

DIVIDENDYIELD

Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.

Dividend Yield Comparison With Top Peers

1M

1Y

3Y

5Y

* All values are in %

Net Profit Vs Dividend Per Share

Image

Suven Life Sciences Ltd

NSE: SUVEN

PRICE

132.6

-4.10 (-3.00%)

stock direction

Last updated : 12 Jul 15:30

SWOT Analysis Of Suven Life Sciences Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

Overview of Dividend

Types of Dividend


Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.


Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.


Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.


Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


×

Historical Market Cap of Suven Life Sciences Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Suven Life Sciences Ltd

Period
Mar '193321
Mar '20272
Mar '21896
Mar '221348
Mar '231057
Mar '242174

* All values are a in crore

×

Historical Revenue of Suven Life Sciences Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Suven Life Sciences Ltd

Period
Jun '2210
Sep '225
Dec '225
Mar '238
Jun '239
Sep '2316
Dec '239
Mar '247

* All values are a in crore

×

Historical EBITDA of Suven Life Sciences Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Suven Life Sciences Ltd

Period
Jun '22-15
Sep '22-21
Dec '22-49
Mar '23-26
Jun '23-22
Sep '23-11
Dec '23-40
Mar '24-26

* All values are a in crore

×

Historical Net Profit of Suven Life Sciences Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Suven Life Sciences Ltd

Period
Jun '22-16
Sep '22-23
Dec '22-51
Mar '23-28
Jun '23-24
Sep '23-13
Dec '23-42
Mar '24-27

* All values are a in crore

About Suven Life Sciences Ltd

About Suven Life Sciences Ltd

    Suven Life Sciences Limited, erstwhile Suven Pharmaceuticals (SPL), is in the business of Contract Research And Manufacturing Services (CRAMS, catering to the needs of global life science industry and fine chemical majors. Suven's CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The company services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from project-based transactions into relationship-based business. The Company has two international wholly owned subsidiary companies and one Indian wholly owned subsidiary company as on 31st March 2019. Suven Life Sciences Limited began operations in 1989 as specialty chemicals provider. Incorporated in Mar.'89 as a private limited company, Suven Pharmaceuticals (SPL) was converted into a public limited company in Jan.'95. It was promoted by Sudharani Jasti and Venkateswarlu Jasti, who is the present Chairman & CEO of the company. In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. During 1999-2000, the company has acquired a small pilot plant in Jeedimetla Industrial Estate, Hyderabad. During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 have registered a growth of 71% over the previous year. The Profit After Tax (PAT) has also registered a growth of 325% over the previous year. The company has successfully achieved the re-certification of ISO 9002 during the year 2000-01. During the financial year ended 31 March 2014, Suven's Drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators. In addition, D-4010 and G3031 are undergoing regulatory toxicological studies in preparation for them being moving into Phase 1 clinical trial during 2014-15. During the year 2014, Suven has made significant inroads into drug discovery with a specialization on CNS-based programmes targeting unmet medical needs. The Company enjoys a unique position in the India (and Asia) as one of the prominent company with technologies under central nervous system (CNS). It has funded drug discovery for nine years resulting in a robust pipeline of 14 molecules at various stages of development. Suven's discovery assets address niche therapeutic areas like cognition, depression, obesity and pain management. In FY14, the Company filed one ANDA with the USFDA authorities for Malathion lotion, a head-lice product with sales potential estimated at US$35 million. In 2013-14, it granted the exclusive license to Taro Pharmaceuticals to market the product in the US, Canada and Mexico, which is expected to generate revenues and royalty in 2014-15. During FY2015, Suven's lead clinical candidate SUVN-502 has successfully completed Phase 1b clinical trial thus paving the way for the co-pound to move into Proof of Concept (PoC) Phase 2a study. In addition to above compounds, SUVN D-4010 is in its final stages of completing regulatory toxicological studies which will enable it to move into Phase 1 clinical trial in USA. During the FY2015, the Company has issued and allotted 104,53,690 equity shares of Re 1/- each at a premium of Rs 190.32 per share by way of QIP Issue in accordance with the SEBI ICDR guidelines. During FY15, the Company's main focus stayed on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. During FY15, the Company added two new clients to its CRAMS business. It commenced operations at its Vishakhapatnam unit and shifted the manufacturing intermediates for a specialty chemical product to this unit. The shift not only optimized capacities at its CRAMS facilities but also made the CRAMS operations more efficient. During FY2017, the company has spent Rs. 6973 lakhs on innovative R&D in CNS therapies accounting for 13% on sales. Its focus remained on discovering, developing and commercializing novel pharmaceutical products, which are first in class CNS therapies through use of GPCR targets. During FY 2017, the Company has invested a sum of Rs 6501 lakhs in Suven Neurosciences Inc., a wholly owned subsidiary, for its business purpose. In FY2018, the company has spent Rs 6,390 lakhs on innovative R&D in CNS therapies accounting for 10% on sales. During the year 2019, subject to approval of NCLT and other stakeholders the Company's Board considered and decided that the Company shall demerge CRAMS undertaking on a going concern basis to its wholly owned subsidiary, Suven Pharmaceuticals Limited (SPL) through a Scheme of Arrangement between SLSL and SPL keeping in view the expected growth prospects in both CRAMS and discovery business, which shall not only enable both the businesses to grow independently with their focused vision, strategies and operations, but also contribute significantly towards unlocking the potential value of the businesses for the shareholders. The consideration for demerger shall be issue of 1 fully paid up equity share of face value of Re 1/- each of SPL for every 1 fully paid up equity share of face value of Re 1/- each held by each shareholder in the Demerged Company (SLSL) as on the Record Date, thereby resulting in a mirror shareholding of SLSL in SPL. The Company invested a sum of Rs.13,636 lakhs in Suven Neurosciences, Inc., for its business purpose. The Company acquired entire share capital of Rs.1 lakh in Suven Pharmaceuticals Limited identified as Resulting Company for the purpose of Scheme of Arrangement (Demerger) and as of 31st March, 2019 no investments were made in newly formed Suven Pharma, Inc. in USA. During the FY 2018-2019, Suven Pharmaceuticals Limited in India and Suven Pharma, Inc., in USA have become subsidiary companies.

Suven Life Sciences Ltd News Hub

News

Suven Life Sciences to convene AGM

Suven Life Sciences announced that the 35th Annual General Meeting(AGM) of the company wil...

Read more

07 May 202412:58

News

Suven Life Sciences to announce Quarterly Result

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 6 May ...

Read more

29 Apr 202419:07

News

Suven Life Sciences to hold board meeting

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 30 Jan...

Read more

24 Jan 202413:53

News

Suven Life Sciences schedules board meeting

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 4 Nove...

Read more

30 Oct 202316:22

News

Suven Life Sciences announces board meeting date

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 8 Augu...

Read more

02 Aug 202316:49

News

Suven Life Sciences AGM scheduled

Suven Life Sciences announced that the 34th Annual General Meeting (AGM) of the company wi...

Read more

10 May 202312:27

FAQs for dividends of Suven Life Sciences Ltd

What is the current market price of Suven Life Sciences Ltd Ltd as of July 14, 2024?

The current market price of Suven Life Sciences Ltd Ltd stands at 132.6 per share.

What dividend did Suven Life Sciences Ltd declare in the last fiscal year?

In the last fiscal year, Suven Life Sciences Ltd declared a dividend totaling ₹0.0.

What is the most recent dividend declared by Suven Life Sciences Ltd?

Suven Life Sciences Ltd recently declared a dividend of 0.0 in the latest quarter

How many times has Suven Life Sciences Ltd declared dividends in the current fiscal year

Suven Life Sciences Ltd has declared dividends 4 times totaling ₹0 in the current fiscal year (FY2023-2024).

How many times did Suven Life Sciences Ltd declare dividends in the previous fiscal year?

In the previous fiscal year (FY2022-2023), Suven Life Sciences Ltd declared dividends 4 times totaling ₹0.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199